Therapeutics of Alzheimer's disease: Past, present and future

Neuropharmacology

Volumn 76, Issue PART A, 2014, Pages 27-50

  Anand, R ^a   Gill, Kiran Dip ^b   Mahdi, Abbas Ali ^c  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Neurofibrillary tangles; Neuropharmacology

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ADENOSINE RECEPTOR; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ASTEMIZOLE; AVAGACESTAT; BAPINEUZUMAB; BENZIMIDAZOLE; BETA SECRETASE; BEZAFIBRATE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ETAZOLATE; FLURBIPROFEN; GALANTAMINE; GAMMA SECRETASE; INSULIN; LANSOPRAZOLE; MEMANTINE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID; PHENSERINE; RIVASTIGMINE; SEROTONIN RECEPTOR; TACRINE; TARENFLURBIL; TAU PROTEIN; UNINDEXED DRUG;

ALZHEIMER DISEASE; BEHAVIOR; DEMENTIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; HEREDITY; HUMAN; LIVER TOXICITY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ALZHEIMER'S DISEASE; AMYLOID; DEMENTIA; NEUROFIBRILLARY TANGLES; NEUROPHARMACOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 84886600387     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.07.004     Document Type: Review

References (408)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
2. 5th Conference Clinical Trials on Alzheimer's Disease The Journal of Nutrition, Health & Aging 16 2012 795 872
3. P.A. Adlard, R.A. Cherny, D.I. Finkelstein, E. Gautier, E. Robb, M. Cortes, I. Volitakis, X. Liu, J.P. Smith, K. Perez, K. Laughton, Q.X. Li, S.A. Charman, J.A. Nicolazzo, S. Wilkins, K. Deleva, T. Lynch, G. Kok, C.W. Ritchie, R.E. Tanzi, R. Cappai, C.L. Masters, K.J. Barnham, and A.I. Bush Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 59 2008 43 55 (Pubitemid 351905863)
4. O. Adolfsson, M. Pihlgren, N. Toni, Y. Varisco, A.L. Buccarello, K. Antoniello, S. Lohmann, K. Piorkowska, V. Gafner, J.K. Atwal, J. Maloney, M. Chen, A. Gogineni, R.M. Weimer, D.L. Mortensen, M. Friesenhahn, C. Ho, R. Paul, A. Pfeifer, A. Muhs, and R.J. Watts An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta J. Neurosci. 32 2012 9677 9689
5. H.H. Ahmed Modulatory effects of vitamin E, acetyl-L-carnitine and alpha-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model Exp. Toxicol. Pathol. 64 2012 549 556
6. P.S. Aisen, S. Gauthier, S.H. Ferris, D. Saumier, D. Haine, D. Garceau, A. Duong, J. Suhy, J. Oh, W.C. Lau, and J. Sampalis Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch. Med. Sci. 7 2011 102 111
7. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, and L.J. Thal Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826 (Pubitemid 37430117)
8. P.S. Aisen, L.S. Schneider, M. Sano, R. Diaz-Arrastia, C.H. van Dyck, M.F. Weiner, T. Bottiglieri, S. Jin, K.T. Stokes, R.G. Thomas, and L.J. Thal High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 300 2008 1774 1783
9. R.F. Allegri, and A. Guekht Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia Drugs Today (Barc) 48 Suppl. A 2012 25 41
10. A. Andrieux, P. Salin, A. Schweitzer, M. Begou, B. Pachoud, P. Brun, S. Gory-Faure, P. Kujala, M.F. Suaud-Chagny, G. Hofle, and D. Job Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia Biol. Psychiatry 60 2006 1224 1230 (Pubitemid 44693534)
11. A.S. Anisuzzaman, J. Uwada, T. Masuoka, H. Yoshiki, M. Nishio, Y. Ikegaya, N. Takahashi, N. Matsuki, Y. Fujibayashi, Y. Yonekura, T. Momiyama, and I. Muramatsu Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus J. Neurochem. 126 3 2013 360 371
12. X. Anton Alvarez, and P. Fuentes Cerebrolysin in Alzheimer's disease Drugs Today (Barc) 47 2011 487 513
13. Y. Aracava, E.F. Pereira, A. Maelicke, and E.X. Albuquerque Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons J. Pharmacol. Exp. Ther. 312 2005 1195 1205 (Pubitemid 40293781)
14. O. Arancio, H.P. Zhang, X. Chen, C. Lin, F. Trinchese, D. Puzzo, S. Liu, A. Hegde, S.F. Yan, A. Stern, J.S. Luddy, L.F. Lue, D.G. Walker, A. Roher, M. Buttini, L. Mucke, W. Li, A.M. Schmidt, M. Kindy, P.A. Hyslop, D.M. Stern, and S.S. Du Yan RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice EMBO J. 23 2004 4096 4105 (Pubitemid 39472430)
15. G.W. Arendash, T. Mori, C. Cao, M. Mamcarz, M. Runfeldt, A. Dickson, K. Rezai-Zadeh, J. Tane, B.A. Citron, X. Lin, V. Echeverria, and H. Potter Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice J. Alzheimers Dis. 17 2009 661 680
16. J.R. Atack Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA Pharmacol. Ther. 125 2010 11 26
17. H. Atamna, A. Nguyen, C. Schultz, K. Boyle, J. Newberry, H. Kato, and B.N. Ames Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways FASEB J. 22 2008 703 712 (Pubitemid 351348123)
18. A. Atri, J.L. Molinuevo, O. Lemming, Y. Wirth, I. Pulte, and D. Wilkinson Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alzheimers Res. Ther. 5 2013 6
19. C.S. Atwood, M.E. Obrenovich, T. Liu, H. Chan, G. Perry, M.A. Smith, and R.N. Martins Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta Brain Res. Brain Res. Rev. 43 2003 1 16 (Pubitemid 37130077)
20. S. Bachurin, E. Bukatina, N. Lermontova, S. Tkachenko, A. Afanasiev, V. Grigoriev, I. Grigorieva, Y. Ivanov, S. Sablin, and N. Zefirov Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer Ann. N. Y. Acad. Sci. 939 2001 425 435 (Pubitemid 32620096)
21. N. Badiola, V. Alcalde, A. Pujol, L.M. Munter, G. Multhaup, A. Lleo, M. Coma, M. Soler-Lopez, and P. Aloy The proton-pump inhibitor lansoprazole enhances amyloid beta production PLoS One 8 2013 e58837
22. M. Bajda, N. Guzior, M. Ignasik, and B. Malawska Multi-target-directed ligands in Alzheimer's disease treatment Curr. Med. Chem. 18 2011 4949 4975
23. S. Bakchine, and H. Loft Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study J. Alzheimers Dis. 13 2008 97 107 (Pubitemid 351365621)
24. S. Banerjee, J. Hellier, R. Romeo, M. Dewey, M. Knapp, C. Ballard, R. Baldwin, P. Bentham, C. Fox, C. Holmes, C. Katona, C. Lawton, J. Lindesay, G. Livingston, N. McCrae, E. Moniz-Cook, J. Murray, S. Nurock, M. Orrell, J. O'Brien, M. Poppe, A. Thomas, R. Walwyn, K. Wilson, and A. Burns Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine Health Technol. Assess. 17 2013 1 166
25. A.M. Barron, S.J. Fuller, G. Verdile, and R.N. Martins Reproductive hormones modulate oxidative stress in Alzheimer's disease Antioxid. Redox Signal 8 2006 2047 2059 (Pubitemid 46489630)
26. L. Baum, C.W. Lam, S.K. Cheung, T. Kwok, V. Lui, J. Tsoh, L. Lam, V. Leung, E. Hui, C. Ng, J. Woo, H.F. Chiu, W.B. Goggins, B.C. Zee, K.F. Cheng, C.Y. Fong, A. Wong, H. Mok, M.S. Chow, P.C. Ho, S.P. Ip, C.S. Ho, X.W. Yu, C.Y. Lai, M.H. Chan, S. Szeto, I.H. Chan, and V. Mok Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease J. Clin. Psychopharmacol. 28 2008 110 113
27. M.F. Beal Mechanisms of excitotoxicity in neurologic diseases FASEB J. 6 1992 3338 3344 (Pubitemid 23007098)
28. A.J. Beel, and C.R. Sanders Substrate specificity of gamma-secretase and other intramembrane proteases Cell Mol. Life Sci. 65 2008 1311 1334
29. N.L. Benowitz, F. Kuyt, P. Jacob 3rd, R.T. Jones, and A.L. Osman Cotinine disposition and effects Clin. Pharmacol. Ther. 34 1983 604 611 (Pubitemid 14247719)
30. J. Berger-Sweeney The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers Neurosci. Biobehav Rev. 27 2003 401 411 (Pubitemid 36999838)
31. A. Bilikiewicz, and W. Gaus Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease J. Alzheimers Dis. 6 2004 17 26 (Pubitemid 38418554)
32. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst. Rev. 2006 CD005593
33. E.M. Blalock, J.T. Phelps, T. Pancani, J.L. Searcy, K.L. Anderson, J.C. Gant, J. Popovic, M.G. Avdiushko, D.A. Cohen, K.C. Chen, N.M. Porter, and O. Thibault Effects of long-term pioglitazone treatment on peripheral and central markers of aging PLoS One 5 2010 e10405
34. K. Blennow, H. Zetterberg, J.O. Rinne, S. Salloway, J. Wei, R. Black, M. Grundman, and E. Liu Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease Arch. Neurol. 69 2012 1002 1010
35. B. Bohrmann, K. Baumann, J. Benz, F. Gerber, W. Huber, F. Knoflach, J. Messer, K. Oroszlan, R. Rauchenberger, W.F. Richter, C. Rothe, M. Urban, M. Bardroff, M. Winter, C. Nordstedt, and H. Loetscher Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta J. Alzheimers Dis. 28 2012 49 69
36. M. Boimel, N. Grigoriadis, A. Lourbopoulos, E. Haber, O. Abramsky, and H. Rosenmann Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice Exp. Neurol. 224 2010 472 485
37. S.C. Bondy, S.X. Guo-Ross, and A.T. Truong Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid Brain Res. 799 1998 91 96 (Pubitemid 28351208)
38. J. Bosel, F. Gandor, C. Harms, M. Synowitz, U. Harms, P.C. Djoufack, D. Megow, U. Dirnagl, H. Hortnagl, K.B. Fink, and M. Endres Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones J. Neurochem. 92 2005 1386 1398 (Pubitemid 40389208)
39. A. Boutajangout, J. Ingadottir, P. Davies, and E.M. Sigurdsson Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain J. Neurochem. 118 2011 658 667
40. E.R. Bowman, and K.H. Mc Jr. Studies on the metabolism of (-)-cotinine in the human J. Pharmacol. Exp. Ther. 135 1962 306 311
41. J.D. Brioni, T.A. Esbenshade, T.R. Garrison, S.R. Bitner, and M.D. Cowart Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease J. Pharmacol. Exp. Ther. 336 2011 38 46
42. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimers Dement. 3 2007 186 191 (Pubitemid 46825511)
43. E. Bruel-Jungerman, P.J. Lucassen, and F. Francis Cholinergic influences on cortical development and adult neurogenesis Behav. Brain Res. 221 2011 379 388
44. K.R. Brunden, B. Zhang, J. Carroll, Y. Yao, J.S. Potuzak, A.M. Hogan, M. Iba, M.J. James, S.X. Xie, C. Ballatore, A.B. Smith 3rd, V.M. Lee, and J.Q. Trojanowski Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy J. Neurosci. 30 2010 13861 13866
45. L. Buee, T. Bussiere, V. Buee-Scherrer, A. Delacourte, and P.R. Hof Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Brain Res. Rev. 33 2000 95 130
46. B. Buisson, and D. Bertrand Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor Mol. Pharmacol. 53 1998 555 563 (Pubitemid 28162880)
47. M.S. Burkhardt, J.K. Foster, S.M. Laws, L.D. Baker, S. Craft, S.E. Gandy, B.G. Stuckey, R. Clarnette, D. Nolan, B. Hewson-Bower, and R.N. Martins Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4 J. Alzheimers Dis. 6 2004 221 228 (Pubitemid 38823256)
48. D.A. Butterfield, and C.B. Pocernich The glutamatergic system and Alzheimer's disease: therapeutic implications CNS Drugs 17 2003 641 652 (Pubitemid 36920542)
49. J.D. Buxbaum, E.I. Cullen, and L.T. Friedhoff Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients Front Biosci. 7 2002 a50 a59
50. C. Cabrol, M.A. Huzarska, C. Dinolfo, M.C. Rodriguez, L. Reinstatler, J. Ni, L.A. Yeh, G.D. Cuny, R.L. Stein, D.J. Selkoe, and M.A. Leissring Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening PLoS One 4 2009 e5274
51. P.M. Canas, L.O. Porciuncula, G.M. Cunha, C.G. Silva, N.J. Machado, J.M. Oliveira, C.R. Oliveira, and R.A. Cunha Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway J. Neurosci. 29 2009 14741 14751
52. S. Capsoni, S. Marinelli, M. Ceci, D. Vignone, G. Amato, F. Malerba, F. Paoletti, G. Meli, A. Viegi, F. Pavone, and A. Cattaneo Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice PLoS One 7 2012 e37555
53. D.P. Cardinali, A.M. Furio, and L.I. Brusco Clinical aspects of melatonin intervention in Alzheimer's disease progression Curr. Neuropharmacol. 8 2010 218 227
54. G. Casadesus, K.M. Webber, C.S. Atwood, M.A. Pappolla, G. Perry, R.L. Bowen, and M.A. Smith Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice Biochim. Biophys. Acta 1762 2006 447 452 (Pubitemid 43344306)
55. M. Cavas, and J.F. Navarro Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 56 67 (Pubitemid 43021322)
56. X. Chai, S. Wu, T.K. Murray, R. Kinley, C.V. Cella, H. Sims, N. Buckner, J. Hanmer, P. Davies, M.J. O'Neill, M.L. Hutton, and M. Citron Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression J. Biol. Chem. 286 2011 34457 34467
57. D.T. Chalmers, and S.J. Watson Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study Brain Res. 561 1991 51 60
58. A. Chan, J. Paskavitz, R. Remington, S. Rasmussen, and T.B. Shea Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension Am. J. Alzheimers Dis. Other Demen. 23 2008 571 585
59. W.P. Chang, X. Huang, D. Downs, J.R. Cirrito, G. Koelsch, D.M. Holtzman, A.K. Ghosh, and J. Tang Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice FASEB J. 25 2011 775 784
60. V. Chauhan, L. Ji, and A. Chauhan Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease Biogerontology 9 2008 381 389
61. P.L. Chazot Therapeutic potential of histamine H3 receptor antagonists in dementias Drug News Perspect. 23 2010 99 103
62. X. Chen, D.G. Walker, A.M. Schmidt, O. Arancio, L.F. Lue, and S.D. Yan RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease Curr. Mol. Med. 7 2007 735 742
63. Y.F. Cheng, C. Wang, H.B. Lin, Y.F. Li, Y. Huang, J.P. Xu, and H.T. Zhang Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in rats Psychopharmacology (Berl) 212 2010 181 191
64. B.V. Chernyak, Y.N. Antonenko, L.V. Domnina, O.Y. Ivanova, K.G. Lyamzaev, A.V. Pustovidko, T.I. Rokitskaya, I.I. Severina, R.A. Simonyan, T.A. Trendeleva, and R.A. Zvyagilskaya Novel penetrating cations for targeting mitochondria Curr. Pharm. Des. 19 2013 2795 2806
65. W.L. Chien, K.C. Liang, C.M. Teng, S.C. Kuo, F.Y. Lee, and W.M. Fu Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole Mol. Pharmacol. 63 2003 1322 1328
66. W.L. Chien, K.C. Liang, C.M. Teng, S.C. Kuo, F.Y. Lee, and W.M. Fu Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1 Eur. J. Neurosci. 21 2005 1679 1688
67. S.H. Choi, S. Aid, L. Caracciolo, S.S. Minami, T. Niikura, Y. Matsuoka, R.S. Turner, M.P. Mattson, and F. Bosetti Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease J. Neurochem. 124 2013 59 68
68. L. Cibickova, V. Palicka, N. Cibicek, E. Cermakova, S. Micuda, L. Bartosova, and D. Jun Differential effects of statins and alendronate on cholinesterases in serum and brain of rats Physiol. Res. 56 2007 765 770
69. A. Cifariello, A. Pompili, and A. Gasbarri 5-HT(7) receptors in the modulation of cognitive processes Behav. Brain Res. 195 2008 171 179
70. A. Claxton, L.D. Baker, C.W. Wilkinson, E.H. Trittschuh, D. Chapman, G.S. Watson, B. Cholerton, S.R. Plymate, M. Arbuckle, and S. Craft Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease J. Alzheimers Dis. 35 2013 789 797
71. F. Clerici, N. Vanacore, A. Elia, S. Spila-Alegiani, S. Pomati, R. Da Cas, R. Raschetti, and C. Mariani Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study Neurol. Sci. 33 2012 23 31
72. C. Coban, S. Koyama, F. Takeshita, S. Akira, and K.J. Ishii Molecular and cellular mechanisms of DNA vaccines Hum. Vaccin. 4 2008 453 456
73. J.T. Cole, D.C. McMullen, W.S. Kean, A.M. Yarnell, J.J. Lucky, M.A. Selak, J.E. Buonora, N.E. Grunberg, A. Verma, and W.D. Watson Manipulating thyroid status alters endoplasmic reticulum calcium homeostasis in rat cerebellum Indian J. Exp. Biol. 50 2012 7 18
74. S. Collina, R. Gaggeri, A. Marra, A. Bassi, S. Negrinotti, F. Negri, and D. Rossi Sigma receptor modulators: a patent review Expert Opin. Ther. Pat. 23 2013 597 613
75. 2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 103 2006 12867 12872 (Pubitemid 44298653)
76. E.E. Congdon, J.W. Wu, N. Myeku, Y.H. Figueroa, M. Herman, P.S. Marinec, J.E. Gestwicki, C.A. Dickey, W.H. Yu, and K.E. Duff Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo Autophagy 8 2012 609 622
77. Z. Corbyn New set of Alzheimer's trials focus on prevention The Lancet 381 2013 614 615
78. A. Cordle, J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth Mechanisms of statin-mediated inhibition of small G-protein function J. Biol. Chem. 280 2005 34202 34209 (Pubitemid 41443145)
79. A. Cordle, and G. Landreth 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses J. Neurosci. 25 2005 299 307 (Pubitemid 40105600)
80. C. Cornelius, J. Fastbom, B. Winblad, and M. Viitanen Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population Neuroepidemiology 23 2004 135 143 (Pubitemid 38490224)
81. M.M. Corrada, C.H. Kawas, J. Hallfrisch, D. Muller, and R. Brookmeyer Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging Alzheimers Dement 1 2005 11 18 (Pubitemid 43348849)
82. J. Coyle, and P. Kershaw Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease Biol. Psychiatry 49 2001 289 299 (Pubitemid 32178438)
83. A. Daccache, C. Lion, N. Sibille, M. Gerard, C. Slomianny, G. Lippens, and P. Cotelle Oleuropein and derivatives from olives as Tau aggregation inhibitors Neurochem. Int. 58 2011 700 707
84. O.P. Dall'Igna, P. Fett, M.W. Gomes, D.O. Souza, R.A. Cunha, and D.R. Lara Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice Exp. Neurol. 203 2007 241 245 (Pubitemid 44821181)
85. T. Dantoine, S. Auriacombe, M. Sarazin, H. Becker, J.J. Pere, and I. Bourdeix Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment Int. J. Clin. Pract. 60 2006 110 118 (Pubitemid 43732587)
86. K.A. DaSilva, M.E. Brown, J.E. Cousins, R.V. Rappaport, I. Aubert, D. Westaway, and M. JoAnne scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease Alzheimer's Demen. The J. Alzheimer's Assoc. 5 2009 P425
87. H. Davtyan, A. Ghochikyan, I. Petrushina, A. Hovakimyan, A. Davtyan, A. Poghosyan, A.M. Marleau, N. Movsesyan, A. Kiyatkin, S. Rasool, A.K. Larsen, P.J. Madsen, K.M. Wegener, D.K. Ditlevsen, D.H. Cribbs, L.O. Pedersen, and M.G. Agadjanyan Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial J. Neurosci. 33 2013 4923 4934
88. S.M. de la Monte, A. Jhaveri, B.A. Maron, and J.R. Wands Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery J. Neuropathol. Exp. Neurol. 66 2007 272 283 (Pubitemid 46559020)
89. R. Deane, I. Singh, A.P. Sagare, R.D. Bell, N.T. Ross, B. LaRue, R. Love, S. Perry, N. Paquette, R.J. Deane, M. Thiyagarajan, T. Zarcone, G. Fritz, A.E. Friedman, B.L. Miller, and B.V. Zlokovic A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease J. Clin. Invest. 122 2012 1377 1392
90. C.A. Dickey, A. Kamal, K. Lundgren, N. Klosak, R.M. Bailey, J. Dunmore, P. Ash, S. Shoraka, J. Zlatkovic, C.B. Eckman, C. Patterson, D.W. Dickson, N.S. Nahman Jr., M. Hutton, F. Burrows, and L. Petrucelli The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Invest. 117 2007 648 658 (Pubitemid 46348523)
91. M.C. Dinamarca, J.A. Rios, and N.C. Inestrosa Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease Front Physiol. 3 2012 464
92. R. Dockens, J.S. Wang, L. Castaneda, O. Sverdlov, S.P. Huang, R. Slemmon, H. Gu, O. Wong, H. Li, R.M. Berman, C. Smith, C.F. Albright, and G. Tong A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects Clin. Pharmacokinet. 51 2012 681 693
93. R.C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frolich, A. Haag, U. Hemmeter, S. Paulsen, S.J. Teipel, S. Brettschneider, A. Spottke, C. Nolker, H.J. Moller, X. Wei, M. Farlow, N. Sommer, and W.H. Oertel Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J. Neurol. Neurosurg. Psychiatry 75 2004 1472 1474 (Pubitemid 39279821)
94. R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, S. Forster, Y. Winter, J.P. Bach, J. Popp, J. Alferink, J. Wiltfang, K. Buerger, M. Otto, P. Antuono, M. Jacoby, R. Richter, J. Stevens, I. Melamed, J. Goldstein, S. Haag, S. Wietek, M. Farlow, and F. Jessen Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Lancet Neurol. 12 2013 233 243
95. R.S. Doody, S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 372 2008 207 215 (Pubitemid 351978110)
96. B.D. Drever, G. Riedel, and B. Platt The cholinergic system and hippocampal plasticity Behav. Brain Res. 221 2011 505 514
97. M. Dumont, C. Stack, C. Elipenahli, S. Jainuddin, M. Gerges, N. Starkova, N.Y. Calingasan, L. Yang, D. Tampellini, A.A. Starkov, R.B. Chan, G. Di Paolo, A. Pujol, and M.F. Beal Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice Hum. Mol. Genet. 21 2012 5091 5105
98. M. Dumont, E. Wille, N.Y. Calingasan, D. Tampellini, C. Williams, G.K. Gouras, K. Liby, M. Sporn, C. Nathan, M. Flint Beal, and M.T. Lin Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease J. Neurochem. 109 2009 502 512
99. M.W. Dysken, P.D. Guarino, J.E. Vertrees, S. Asthana, M. Sano, M. Llorente, M. Pallaki, S. Love, G.D. Schellenberg, J.R. McCarten, J. Malphurs, S. Prieto, P. Chen, D.J. Loreck, S. Carney, G. Trapp, R.S. Bakshi, J.E. Mintzer, J.L. Heidebrink, A. Vidal-Cardona, L.M. Arroyo, A.R. Cruz, N.W. Kowall, M.P. Chopra, S. Craft, S. Thielke, C.L. Turvey, C. Woodman, K.A. Monnell, K. Gordon, J. Tomaska, and G. Vatassery Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data Alzheimers Dement 2013 pii: S1552-5260(13)00046-0
100. V. Echeverria, and R. Zeitlin Cotinine: a potential new therapeutic agent against Alzheimer's disease CNS Neurosci. Ther. 18 2012 517 523
101. V. Echeverria, R. Zeitlin, S. Burgess, S. Patel, A. Barman, G. Thakur, M. Mamcarz, L. Wang, D.B. Sattelle, D.A. Kirschner, T. Mori, R.M. Leblanc, R. Prabhakar, and G.W. Arendash Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice J. Alzheimers Dis. 24 2011 817 835
102. M. Egan, R. Yaari, L. Liu, M. Ryan, Y. Peng, C. Lines, and D. Michelson Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD Curr. Alzheimer Res. 9 2012 481 490
103. C.T. Ekdahl, Z. Kokaia, and O. Lindvall Brain inflammation and adult neurogenesis: the dual role of microglia Neuroscience 158 2009 1021 1029
104. T. Engel, P. Goni-Oliver, J.J. Lucas, J. Avila, and F. Hernandez Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J. Neurochem. 99 2006 1445 1455 (Pubitemid 44924224)
105. M. Eriksdotter-Jonhagen, B. Linderoth, G. Lind, L. Aladellie, O. Almkvist, N. Andreasen, K. Blennow, N. Bogdanovic, V. Jelic, A. Kadir, A. Nordberg, E. Sundstrom, L.O. Wahlund, A. Wall, M. Wiberg, B. Winblad, A. Seiger, P. Almqvist, and L. Wahlberg Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease Dement Geriatr. Cogn. Disord. 33 2012 18 28
106. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J. Clin. Invest. 112 2003 440 449 (Pubitemid 38063773)
107. M.H. Eskelinen, T. Ngandu, J. Tuomilehto, H. Soininen, and M. Kivipelto Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study J. Alzheimers Dis. 16 2009 85 91
108. J. Fan, J. Donkin, and C. Wellington Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E Biofactors 35 2009 239 248
109. N. Farina, M.G. Isaac, A.R. Clark, J. Rusted, and N. Tabet Vitamin E for Alzheimer's dementia and mild cognitive impairment Cochrane Database Syst. Rev. 11 2012 CD002854
110. L.E. Farrimond, E. Roberts, and R. McShane Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review BMJ Open 2 2012
111. H.H. Feldman, R.S. Doody, M. Kivipelto, D.L. Sparks, D.D. Waters, R.W. Jones, E. Schwam, R. Schindler, J. Hey-Hadavi, D.A. DeMicco, and A. Breazna Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 74 2010 956 964
112. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie, Y. Huang, A. Jorm, C. Mathers, P.R. Menezes, E. Rimmer, and M. Scazufca Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117 (Pubitemid 41797645)
113. A. Fisher Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease Neurotherapeutics 5 2008 433 442 (Pubitemid 351952486)
114. A. Fisher Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease J. Neurochem. 120 Suppl. 1 2012 22 33
115. A. Fisher, R. Brandeis, R.H. Bar-Ner, M. Kliger-Spatz, N. Natan, H. Sonego, I. Marcovitch, and Z. Pittel AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease J. Mol. Neurosci. 19 2002 145 153 (Pubitemid 35013348)
116. L. Fjord-Larsen, P. Kusk, D.F. Emerich, C. Thanos, M. Torp, B. Bintz, J. Tornoe, A.H. Johnsen, and L.U. Wahlberg Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer Gene Ther. 19 2012 1010 1017
117. A.S. Fleisher, D. Truran, J.T. Mai, J.B. Langbaum, P.S. Aisen, J.L. Cummings, C.R. Jack Jr., M.W. Weiner, R.G. Thomas, L.S. Schneider, and P.N. Tariot Chronic divalproex sodium use and brain atrophy in Alzheimer disease Neurology 77 2011 1263 1271
118. A.C. Fonseca, R. Resende, C.R. Oliveira, and C.M. Pereira Cholesterol and statins in Alzheimer's disease: current controversies Exp. Neurol. 223 2010 282 293
119. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, L. Jenkins, and M. Koller Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 64 2005 1563 1572 (Pubitemid 40617692)
120. L.T. Friedhoff, E.I. Cullen, N.S. Geoghagen, and J.D. Buxbaum Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide Int. J. Neuropsychopharmacol. 4 2001 127 130 (Pubitemid 32587379)
121. W. Froestl, A. Muhs, and A. Pfeifer Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes J. Alzheimers Dis. 33 2013 547 658
122. A.L. Fu, C.Y. Zhou, and X. Chen Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease Neuropharmacology 58 2010 722 729
123. Q. Fu, J. Hue, and S. Li Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition J. Neurosci. 27 2007 4154 4164 (Pubitemid 46597154)
124. F. Fumagalli, R. Molteni, F. Calabrese, P.F. Maj, G. Racagni, and M.A. Riva Neurotrophic factors in neurodegenerative disorders: potential for therapy CNS Drugs 22 2008 1005 1019
125. M.D. Gahete, A. Rubio, M. Duran-Prado, J. Avila, R.M. Luque, and J.P. Castano Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients J. Alzheimers Dis. 20 2010 465 475
126. D.R. Galasko, N. Graff-Radford, S. May, S. Hendrix, B.A. Cottrell, S.A. Sagi, G. Mather, M. Laughlin, K.H. Zavitz, E. Swabb, T.E. Golde, M.P. Murphy, and E.H. Koo Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis. Assoc. Disord. 21 2007 292 299 (Pubitemid 350307433)
127. D.R. Galasko, E. Peskind, C.M. Clark, J.F. Quinn, J.M. Ringman, G.A. Jicha, C. Cotman, B. Cottrell, T.J. Montine, R.G. Thomas, and P. Aisen Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch. Neurol. 69 2012 836 841
128. D. Galimberti, L. Ghezzi, and E. Scarpini Immunotherapy against amyloid pathology in Alzheimer's disease J. Neurol. Sci. 2013 pii: S0022-510X(12)00637-5
129. M.L. Garcia, and D.W. Cleveland Going new places using an old MAP: tau, microtubules and human neurodegenerative disease Curr. Opin. Cell Biol. 13 2001 41 48 (Pubitemid 32119291)
130. E.M. Garcia-Martinez, S. Sanz-Blasco, A. Karachitos, M.J. Bandez, F.J.
131. S. Gauthier, P.S. Aisen, S.H. Ferris, D. Saumier, A. Duong, D. Haine, D. Garceau, J. Suhy, J. Oh, W. Lau, and J. Sampalis Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study J. Nutr. Health Aging 13 2009 550 557
132. H. Geerts, A. Spiros, and P. Roberts Failure analysis of dimebon using mechanistic disease modeling: lessons for clinical development of new Alzheimer's disease therapies Alzheimer's Demen. 8 2012 P211
133. D.S. Geldmacher, T. Fritsch, M.J. McClendon, and G. Landreth A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease Arch. Neurol. 68 2011 45 50
134. A.K. Ghosh, M. Brindisi, and J. Tang Developing beta-secretase inhibitors for treatment of Alzheimer's disease J. Neurochem. 120 Suppl. 1 2012 71 83
135. K.E. Gilling, C. Jatzke, M. Hechenberger, and C.G. Parsons Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors Neuropharmacology 56 2009 866 875
136. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, and J.M. Orgogozo Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562 (Pubitemid 40617691)
137. C. Giommarelli, V. Zuco, E. Favini, C. Pisano, F. Dal Piaz, N. De Tommasi, and F. Zunino The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition Cell Mol. Life Sci. 67 2010 995 1004
138. I. Gozes NAP (davunetide) provides functional and structural neuroprotection Curr. Pharm. Des. 17 2011 1040 1044
139. I. Gozes, I. Divinski, and I. Piltzer NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42) BMC Neurosci. 9 Suppl. 3 2008 S3
140. A. Gravius, J. Laszy, M. Pietraszek, K. Saghy, J. Nagel, C. Chambon, N. Wegener, B. Valastro, W. Danysz, and I. Gyertyan Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity Behav. Pharmacol. 22 2011 122 135
141. M.J. Gunasingh, J.E. Philip, B.S. Ashok, R. Kirubagaran, W.C. Jebaraj, G.D. Davis, S. Vignesh, S. Dhandayuthapani, and R. Jayakumar Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism Life Sci. 83 2008 96 102
142. A. Guntert, J. Campbell, M. Saleem, D.P. O'Brien, A.J. Thompson, H.L. Byers, M.A. Ward, and S. Lovestone Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease J. Alzheimers Dis. 21 2010 585 596
143. H. Gutzmann, and D. Hadler Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study J. Neural Transm. Suppl. 54 1998 301 310 (Pubitemid 28539367)
144. H. Hampel, M. Ewers, K. Burger, P. Annas, A. Mortberg, A. Bogstedt, L. Frolich, J. Schroder, P. Schonknecht, M.W. Riepe, I. Kraft, T. Gasser, T. Leyhe, H.J. Moller, A. Kurz, and H. Basun Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study J. Clin. Psychiatry 70 2009 922 931
145. H. Hanyu, T. Sato, A. Kiuchi, H. Sakurai, and T. Iwamoto Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus J. Am. Geriatr. Soc. 57 2009 177 179
146. K.M. Hayden, P.P. Zandi, A.S. Khachaturian, C.A. Szekely, M. Fotuhi, M.C. Norton, J.T. Tschanz, C.F. Pieper, C. Corcoran, C.G. Lyketsos, J.C. Breitner, and K.A. Welsh-Bohmer Does NSAID use modify cognitive trajectories in the elderly? the Cache County study Neurology 69 2007 275 282 (Pubitemid 47205690)
147. P. He, X. Ouyang, S. Zhou, W. Yin, C. Tang, M. Laudon, and S. Tian A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease Horm. Behav. 64 1 2013 1 7
148. E. Hellstrom-Lindahl, H. Moore, and A. Nordberg Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists J. Neurochem. 74 2000 777 784 (Pubitemid 30053751)
149. R. Hellweg, Y. Wirth, W. Janetzky, and S. Hartmann Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD Int. J. Geriatr. Psychiatry 27 2012 651 656
150. C.M. Hernandez, and K.T. Dineley alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? Curr. Drug Targets 13 2012 613 622
151. S.E. Hickman, E.K. Allison, and J. El Khoury Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice J. Neurosci. 28 2008 8354 8360
152. 2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 40 1981 597 604
153. W.D. Hirst, T.O. Stean, D.C. Rogers, D. Sunter, P. Pugh, S.F. Moss, S.M. Bromidge, G. Riley, D.R. Smith, S. Bartlett, C.A. Heidbreder, A.R. Atkins, L.P. Lacroix, L.A. Dawson, A.G. Foley, C.M. Regan, and N. Upton SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models Eur. J. Pharmacol. 553 2006 109 119 (Pubitemid 44779592)
154. L. Ho, L.H. Chen, J. Wang, W. Zhao, S.T. Talcott, K. Ono, D. Teplow, N. Humala, A. Cheng, S.S. Percival, M. Ferruzzi, E. Janle, D.L. Dickstein, and G.M. Pasinetti Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration J. Alzheimers Dis. 16 2009 59 72
155. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R.W. Jones, R. Bullock, S. Love, J.W. Neal, E. Zotova, and J.A. Nicoll Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223 (Pubitemid 351978111)
156. C.R. Hopkins ACS chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic ACS Chem. Neurosci. 2 2011 279 280
157. R. Howard, R. McShane, J. Lindesay, C. Ritchie, A. Baldwin, R. Barber, A. Burns, T. Dening, D. Findlay, C. Holmes, A. Hughes, R. Jacoby, R. Jones, I. McKeith, A. Macharouthu, J. O'Brien, P. Passmore, B. Sheehan, E. Juszczak, C. Katona, R. Hills, M. Knapp, C. Ballard, R. Brown, S. Banerjee, C. Onions, M. Griffin, J. Adams, R. Gray, T. Johnson, P. Bentham, and P. Phillips Donepezil and memantine for moderate-to-severe Alzheimer's disease N. Engl. J. Med. 366 2012 893 903
158. H.H. Hsu Clinical Trials for Disease-modifying Drugs Such as BACE Inhibitors 2010 BACE. John Wiley & Sons, Inc. 197 216
159. S. Hu, A.N. Begum, M.R. Jones, M.S. Oh, W.K. Beech, B.H. Beech, F. Yang, P. Chen, O.J. Ubeda, P.C. Kim, P. Davies, Q. Ma, G.M. Cole, and S.A. Frautschy GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals Neurobiol. Dis. 33 2009 193 206
160. C.H. Hung, Y.S. Ho, and R.C. Chang Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease Ageing Res. Rev. 9 2010 447 456
161. M.D. Ikonomovic, L. Wecker, E.E. Abrahamson, J. Wuu, S.E. Counts, S.D. Ginsberg, E.J. Mufson, and S.T. Dekosky Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease Arch. Neurol. 66 2009 646 651
162. B.P. Imbimbo Why did tarenflurbil fail in Alzheimer's disease? J. Alzheimers Dis. 17 2009 757 760
163. B.P. Imbimbo, F. Panza, V. Frisardi, V. Solfrizzi, G. D'Onofrio, G. Logroscino, D. Seripa, and A. Pilotto Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin. Investig. Drugs 20 2011 325 341
164. B.P. Imbimbo, V. Solfrizzi, and F. Panza Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci. 2 2010
165. J.S. Jacobsen, T.A. Comery, R.L. Martone, H. Elokdah, D.L. Crandall, A. Oganesian, S. Aschmies, Y. Kirksey, C. Gonzales, J. Xu, H. Zhou, K. Atchison, E. Wagner, M.M. Zaleska, I. Das, R.L. Arias, J. Bard, D. Riddell, S.J. Gardell, M. Abou-Gharbia, A. Robichaud, R. Magolda, G.P. Vlasuk, T. Bjornsson, P.H. Reinhart, and M.N. Pangalos Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade Proc. Natl. Acad. Sci. U. S. A. 105 2008 8754 8759 (Pubitemid 351987752)
166. S.R. Jaffrey, H. Erdjument-Bromage, C.D. Ferris, P. Tempst, and S.H. Snyder Protein S-nitrosylation: a physiological signal for neuronal nitric oxide Nat. Cell Biol. 3 2001 193 197 (Pubitemid 32118373)
167. A. Jan, O. Adolfsson, I. Allaman, A.-L. Buccarello, P.J. Magistretti, A. Pfeifer, A. Muhs, and H.A. Lashuel Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species J. Biol. Chem. 286 2011 8585 8596
168. M. Janusz, M. Woszczyna, M. Lisowski, A. Kubis, J. Macala, T. Gotszalk, and J. Lisowski Ovine colostrum nanopeptide affects amyloid beta aggregation FEBS Lett. 583 2009 190 196
169. M. Janusz, and A. Zablocka Colostral proline-rich polypeptides- immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease Curr. Alzheimer Res. 7 2010 323 333
170. H. Javed, M.M. Khan, A. Ahmad, K. Vaibhav, M.E. Ahmad, A. Khan, M. Ashafaq, F. Islam, M.S. Siddiqui, and M.M. Safhi Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type Neuroscience 210 2012 340 352
171. J.Y. Jia, Q.H. Zhao, Y. Liu, Y.Z. Gui, G.Y. Liu, D.Y. Zhu, C. Yu, and Z. Hong Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease Acta Pharmacol. Sin. 34 7 2013 976 982
172. U.K. Jinwal, Y. Miyata, J. Koren 3rd, J.R. Jones, J.H. Trotter, L. Chang, J. O'Leary, D. Morgan, D.C. Lee, C.L. Shults, A. Rousaki, E.J. Weeber, E.R. Zuiderweg, J.E. Gestwicki, and C.A. Dickey Chemical manipulation of hsp70 ATPase activity regulates tau stability J. Neurosci. 29 2009 12079 12088
173. E.J. Johnson A possible role for lutein and zeaxanthin in cognitive function in the elderly Am. J. Clin. Nutr. 96 2012 1161S 1165S
174. D.P. Jones Extracellular redox state: refining the definition of oxidative stress in aging Rejuvenation Res. 9 2006 169 181 (Pubitemid 43856805)
175. R.W. Jones Dimebon disappointment Alzheimers Res. Ther. 2 2010 25
176. M.E. Jonhagen Nerve growth factor treatment in dementia Alzheimer Dis. Assoc. Disord. 14 Suppl. 1 2000 S31 S38
177. J.A. Joseph, N.A. Denisova, G. Arendash, M. Gordon, D. Diamond, B. Shukitt-Hale, and D. Morgan Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model Nutr. Neurosci. 6 2003 153 162 (Pubitemid 36656693)
178. K. Kanninen, T.M. Malm, H.K. Jyrkkanen, G. Goldsteins, V. Keksa-Goldsteine, H. Tanila, M. Yamamoto, S. Yla-Herttuala, A.L. Levonen, and J. Koistinaho Nuclear factor erythroid 2-related factor 2 protects against beta amyloid Mol. Cell Neurosci. 39 2008 302 313
179. S. Karanth, K. Lyson, and S.M. McCann Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami Proc. Natl. Acad. Sci. U. S. A. 90 1993 3383 3387 (Pubitemid 23111370)
180. S.S. Karuppagounder, J.T. Pinto, H. Xu, H.L. Chen, M.F. Beal, and G.E. Gibson Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease Neurochem. Int. 54 2009 111 118
181. N.A. Kelsey, H.M. Wilkins, and D.A. Linseman Nutraceutical antioxidants as novel neuroprotective agents Molecules 15 2010 7792 7814
182. G.F. Kelso, C.M. Porteous, C.V. Coulter, G. Hughes, W.K. Porteous, E.C. Ledgerwood, R.A. Smith, and M.P. Murphy Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties J. Biol. Chem. 276 2001 4588 4596
183. M. Khalili, and F. Hamzeh Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats Iran Biomed. J. 14 2010 59 65
184. T. Kihara, S. Shimohama, H. Sawada, K. Honda, T. Nakamizo, H. Shibasaki, T. Kume, and A. Akaike alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity J. Biol. Chem. 276 2001 13541 13546
185. M.V. King, C.A. Marsden, and K.C. Fone A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory Trends Pharmacol. Sci. 29 2008 482 492
186. M. Kivipelto, E.L. Helkala, M.P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study BMJ 322 2001 1447 1451 (Pubitemid 32575406)
187. A. Klugman, D.P. Naughton, M. Isaac, I. Shah, A. Petroczi, and N. Tabet Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors J. Alzheimers Dis. 30 2012 467 474
188. A.P. Kozikowski, Y. Chen, T. Subhasish, N.E. Lewin, P.M. Blumberg, Z. Zhong, M.A. D'Annibale, W.L. Wang, Y. Shen, and B. Langley Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress ChemMedChem 4 2009 1095 1105
189. L. Kupershmidt, T. Amit, O. Bar-Am, M.B. Youdim, and O. Weinreb The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease Antioxid. Redox Signal 17 2012 860 877
190. D.J. Kwiatkowski, R. Mehl, and H.L. Yin Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin J. Cell Biol. 106 1988 375 384 (Pubitemid 18052185)
191. A.C. Lacerda, U. Marubayashi, and C.C. Coimbra Nitric oxide pathway is an important modulator of heat loss in rats during exercise Brain Res. Bull 67 2005 110 116 (Pubitemid 41225324)
192. M.J. Ladu, C. Reardon, L. Van Eldik, A.M. Fagan, G. Bu, D. Holtzman, and G.S. Getz Lipoproteins in the central nervous system Ann. N. Y. Acad. Sci. 903 2000 167 175 (Pubitemid 30251555)
193. L. Lagostena, M. Rosato-Siri, M. D'Onofrio, R. Brandi, I. Arisi, S. Capsoni, J. Franzot, A. Cattaneo, and E. Cherubini In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction J. Neurosci. 30 2010 885 893
194. D.K. Lahiri, B. Maloney, M.R. Basha, Y.W. Ge, and N.H. Zawia How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD Curr. Alzheimer Res. 4 2007 219 228 (Pubitemid 46557511)
195. D.K. Lahiri, N.H. Zawia, N.H. Greig, K. Sambamurti, and B. Maloney Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model Biogerontology 9 2008 375 379
196. V. Lahmy, J. Meunier, S. Malmstrom, G. Naert, L. Givalois, S.H. Kim, V. Villard, A. Vamvakides, and T. Maurice Blockade of tau hyperphosphorylation and abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer's disease Neuropsychopharmacology 38 9 2013 1706 1723
197. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C.L. Masters, S. Targum, A.I. Bush, R. Murdoch, J. Wilson, and C.W. Ritchie Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7 2008 779 786
198. C.A. Lasagna-Reeves, D.L. Castillo-Carranza, G.R. Jackson, and R. Kayed Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies Curr. Alzheimer Res. 8 2011 659 665
199. C.Y. Lee, and G.E. Landreth The role of microglia in amyloid clearance from the AD brain J. Neural Transm. 117 2010 949 960
200. D. Lee, S.A. Long, J.L. Adams, G. Chan, K.S. Vaidya, T.A. Francis, K. Kikly, J.D. Winkler, C.M. Sung, C. Debouck, S. Richardson, M.A. Levy, W.E. DeWolf Jr., P.M. Keller, T. Tomaszek, M.S. Head, M.D. Ryan, R.C. Haltiwanger, P.H. Liang, C.A. Janson, P.J. McDevitt, K. Johanson, N.O. Concha, W. Chan, S.S. Abdel-Meguid, A.M. Badger, M.W. Lark, D.P. Nadeau, L.J. Suva, M. Gowen, and M.E. Nuttall Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality J. Biol. Chem. 275 2000 16007 16014 (Pubitemid 30366906)
201. J.Y. Lee, J.E. Friedman, I. Angel, A. Kozak, and J.Y. Koh The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice Neurobiol. Aging 25 2004 1315 1321 (Pubitemid 39299169)
202. J. Lee, J.H. Boo, and H. Ryu The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv. Drug Deliv. Rev. 61 2009 1316 1323
203. R.H. Lee, T.Y. Tseng, C.Y. Wu, P.Y. Chen, M.F. Chen, J.S. Kuo, and T.J. Lee Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries PLoS One 7 2012 e40326
204. G. Lefevre, G. Sedek, S.S. Jhee, M.T. Leibowitz, H.L. Huang, A. Enz, S. Maton, L. Ereshefsky, F. Pommier, H. Schmidli, and S. Appel-Dingemanse Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients Clin. Pharmacol. Ther. 83 2008 106 114
205. J. Leszek, A.D. Inglot, M. Janusz, F. Byczkiewicz, A. Kiejna, J. Georgiades, and J. Lisowski Colostrinin proline-rich polypeptide complex from ovine colostrum-a long-term study of its efficacy in Alzheimer's disease Med. Sci. Monit. 8 2002 PI93 PI96
206. M.J. Leyva, F. Degiacomo, L.S. Kaltenbach, J. Holcomb, N. Zhang, J. Gafni, H. Park, D.C. Lo, G.S. Salvesen, L.M. Ellerby, and J.A. Ellman Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models Chem. Biol. 17 2010 1189 1200
207. L. Li, D. Cao, H. Kim, R. Lester, and K. Fukuchi Simvastatin enhances learning and memory independent of amyloid load in mice Ann. Neurol. 60 2006 729 739 (Pubitemid 46061359)
208. M.P. Lichtenstein, P. Carriba, M.A. Baltrons, B. Wojciak-Stothard, J.R. Peterson, A. Garcia, and E. Galea Secretase-independent and RhoGTPase/PAK/ERK- dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives J. Alzheimers Dis. 22 2010 1135 1155
209. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J. Neurosci. 21 2001 8370 8377 (Pubitemid 33051435)
210. A. Limon, J.M. Reyes-Ruiz, and R. Miledi GABAergic drugs and Alzheimer's disease Future Med. Chem. 3 2011 149 153
211. J. Lindsay, D. Laurin, R. Verreault, R. Hebert, B. Helliwell, G.B. Hill, and I. McDowell Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging Am. J. Epidemiol. 156 2002 445 453 (Pubitemid 34976983)
212. S.A. Lipton, and H.S. Chen Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine Cell Death Differ. 11 2004 18 20 (Pubitemid 38111368)
213. B. Liu, J.L. Frost, J. Sun, H. Fu, S. Grimes, P. Blackburn, and C.A. Lemere MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-abeta antibody response and attenuates abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice J. Neurosci. 33 2013 7027 7037
214. F. Liu, K. Iqbal, I. Grundke-Iqbal, G.W. Hart, and C.X. Gong O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 10804 10809 (Pubitemid 38955823)
215. G. Liu, P. Men, P.L. Harris, R.K. Rolston, G. Perry, and M.A. Smith Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance Neurosci. Lett. 406 2006 189 193 (Pubitemid 44311364)
216. A. Lloret, M.C. Badia, N.J. Mora, F.V. Pallardo, M.D. Alonso, and J. Vina Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental J. Alzheimers Dis. 17 2009 143 149
217. J.K. Lodge Vitamin E bioavailability in humans J. Plant Physiol. 162 2005 790 796 (Pubitemid 40772094)
218. D.D. Long, S.R. Armstrong, D.T. Beattie, S.K. Choi, P.R. Fatheree, R.A. Gendron, D. Genov, A.A. Goldblum, P.P. Humphrey, L. Jiang, D.G. Marquess, J.P. Shaw, J.A. Smith, S.D. Turner, and R.G. Vickery Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation Bioorg. Med. Chem. Lett. 22 2012 6048 6052
219. O.L. Lopez, J.T. Becker, A.S. Wahed, J. Saxton, R.A. Sweet, D.A. Wolk, W. Klunk, and S.T. Dekosky Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease J. Neurol. Neurosurg. Psychiatry 80 2009 600 607
220. P.H. Lu, D.A. Masterman, R. Mulnard, C. Cotman, B. Miller, K. Yaffe, E. Reback, V. Porter, R. Swerdloff, and J.L. Cummings Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men Arch. Neurol. 63 2006 177 185 (Pubitemid 43261728)
221. L.F. Lue, D.G. Walker, L. Brachova, T.G. Beach, J. Rogers, A.M. Schmidt, D.M. Stern, and S.D. Yan Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism Exp. Neurol. 171 2001 29 45 (Pubitemid 32848443)
222. W. Luo, F. Dou, A. Rodina, S. Chip, J. Kim, Q. Zhao, K. Moulick, J. Aguirre, N. Wu, P. Greengard, and G. Chiosis Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies Proc. Natl. Acad. Sci. U. S. A. 104 2007 9511 9516 (Pubitemid 47185810)
223. Y. Luo, S. Vali, S. Sun, X. Chen, X. Liang, T. Drozhzhina, E. Popugaeva, and I. Bezprozvanny Abeta42-Binding peptoids as amyloid aggregation inhibitors and detection ligands ACS Chem. Neurosci. 4 6 2013 952 962
224. Q.L. Ma, X. Zuo, F. Yang, O.J. Ubeda, D.J. Gant, M. Alaverdyan, E. Teng, S. Hu, P.P. Chen, P. Maiti, B. Teter, G.M. Cole, and S.A. Frautschy Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice J. Biol. Chem. 288 2013 4056 4065
225. M.L. Maccecchini, M.Y. Chang, C. Pan, V. John, H. Zetterberg, and N.H. Greig Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans J. Neurol. Neurosurg. Psychiatry 83 2012 894 902
226. A. Maczurek, K. Hager, M. Kenklies, M. Sharman, R. Martins, J. Engel, D.A. Carlson, and G. Munch Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease Adv. Drug Deliv. Rev. 60 2008 1463 1470
227. A. Maelicke, A. Hoeffle-Maas, J. Ludwig, A. Maus, M. Samochocki, U. Jordis, and A.K. Koepke Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy J. Mol. Neurosci. 40 2010 135 137
228. G. Maher-Edwards, R. Dixon, J. Hunter, M. Gold, G. Hopton, G. Jacobs, and P. Williams SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study Int. J. Geriatr. Psychiatry 26 2011 536 544
229. G. Maher-Edwards, M. Zvartau-Hind, A.J. Hunter, M. Gold, G. Hopton, G. Jacobs, M. Davy, and P. Williams Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 7 2010 374 385
230. M. Manczak, P. Mao, M.J. Calkins, A. Cornea, A.P. Reddy, M.P. Murphy, H.H. Szeto, B. Park, and P.H. Reddy Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons J. Alzheimers Dis. 20 Suppl. 2 2010 S609 S631
231. J.B. Mannick, C. Schonhoff, N. Papeta, P. Ghafourifar, M. Szibor, K. Fang, and B. Gaston S-Nitrosylation of mitochondrial caspases J. Cell Biol. 154 2001 1111 1116 (Pubitemid 34286189)
232. D. Marazziti, S. Baroni, A. Pirone, G. Giannaccini, L. Betti, L. Schmid, E. Vatteroni, L. Palego, F. Borsini, F. Bordi, I. Piano, C. Gargini, M. Castagna, M. Catena-Dell'osso, and A. Lucacchini Distribution of serotonin receptor of type 6 (5-HT(6)) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study Neurochem. Res. 37 2012 920 927
233. M. Marcade, J. Bourdin, N. Loiseau, H. Peillon, A. Rayer, D. Drouin, F. Schweighoffer, and L. Desire Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing J. Neurochem. 106 2008 392 404 (Pubitemid 351840218)
234. R.A. Marr, E. Rockenstein, A. Mukherjee, M.S. Kindy, L.B. Hersh, F.H. Gage, I.M. Verma, and E. Masliah Neprilysin gene transfer reduces human amyloid pathology in transgenic mice J. Neurosci. 23 2003 1992 1996 (Pubitemid 36368884)
235. C.L. Martel, J.B. Mackic, E. Matsubara, S. Governale, C. Miguel, W. Miao, J.G. McComb, B. Frangione, J. Ghiso, and B.V. Zlokovic Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta J. Neurochem. 69 1997 1995 2004 (Pubitemid 27452746)
236. R.L. Martone, H. Zhou, K. Atchison, T. Comery, J.Z. Xu, X. Huang, X. Gong, M. Jin, A. Kreft, B. Harrison, S.C. Mayer, S. Aschmies, C. Gonzales, M.M. Zaleska, D.R. Riddell, E. Wagner, P. Lu, S.C. Sun, J. Sonnenberg-Reines, A. Oganesian, K. Adkins, M.W. Leach, D.W. Clarke, D. Huryn, M. Abou-Gharbia, R. Magolda, J. Bard, G. Frick, S. Raje, S.B. Forlow, C. Balliet, M.E. Burczynski, P.H. Reinhart, H.I. Wan, M.N. Pangalos, and J.S. Jacobsen Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease J. Pharmacol. Exp. Ther. 331 2009 598 608
237. P.D. Maskell, P. Speder, N.R. Newberry, and I. Bermudez Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors Br. J. Pharmacol. 140 2003 1313 1319 (Pubitemid 38117436)
238. S.M. Massa, T. Yang, Y. Xie, J. Shi, M. Bilgen, J.N. Joyce, D. Nehama, J. Rajadas, and F.M. Longo Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents J. Clin. Invest. 120 2010 1774 1785
239. Y. Matsuoka, A.J. Gray, C. Hirata-Fukae, S.S. Minami, E.G. Waterhouse, M.P. Mattson, F.M. LaFerla, I. Gozes, and P.S. Aisen Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage J. Mol. Neurosci. 31 2007 165 170 (Pubitemid 46742300)
240. Y. Matsuoka, Y. Jouroukhin, A.J. Gray, L. Ma, C. Hirata-Fukae, H.F. Li, L. Feng, L. Lecanu, B.R. Walker, E. Planel, O. Arancio, I. Gozes, and P.S. Aisen A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease J. Pharmacol. Exp. Ther. 325 2008 146 153 (Pubitemid 351439178)
241. A.F. McKoy, J. Chen, T. Schupbach, and M.H. Hecht A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease J. Biol. Chem. 287 2012 38992 39000
242. R. McShane, A. Areosa Sastre, and N. Minakaran Memantine for dementia Cochrane Database Syst. Rev. 2006 CD003154
243. R. Medeiros, M. Kitazawa, A. Caccamo, D. Baglietto-Vargas, T. Estrada-Hernandez, D.H. Cribbs, A. Fisher, and F.M. LaFerla Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline Am. J. Pathol. 179 2011 980 991
244. A.D. Medhurst, J.C. Roberts, J. Lee, C.P. Chen, S.H. Brown, S. Roman, and M.K. Lai Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice Br. J. Pharmacol. 157 2009 130 138
245. H.Y. Meltzer, R. Mills, S. Revell, H. Williams, A. Johnson, D. Bahr, and J.H. Friedman Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis Neuropsychopharmacology 35 2010 881 892
246. R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.H. Huang, R.J. Perez-Polo, B.F. Uretsky, and Y. Birnbaum The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation Am. J. Physiol. Heart Circ. Physiol. 293 2007 H1918 H1928
247. J.J. Miguel-Hidalgo, I.A. Paul, V. Wanzo, and P.K. Banerjee Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40 Eur. J. Pharmacol. 692 2012 38 45
248. R.C. Mohs The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials Genes Brain Behav. 4 2005 129 133 (Pubitemid 40559139)
249. M.C. Morris, D.A. Evans, J.A. Schneider, C.C. Tangney, J.L. Bienias, and N.T. Aggarwal Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease J. Alzheimers Dis. 9 2006 435 443 (Pubitemid 44253359)
250. D.E. Moss, P. Berlanga, M.M. Hagan, H. Sandoval, and C. Ishida Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type Alzheimer Dis. Assoc. Disord. 13 1999 20 25 (Pubitemid 29176518)
251. D.E. Moss, R.G. Fariello, J. Sahlmann, I. Sumaya, F. Pericle, and E. Braglia A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease Br. J. Clin. Pharmacol. 75 2013 1231 1239
252. M. Motawaj, A. Burban, E. Davenas, and J.M. Arrang Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease J. Pharmacol. Exp. Ther. 336 2011 479 487
253. M. Motawaj, A. Burban, E. Davenas, F. Gbahou, R. Faucard, S. Morisset, and J.M. Arrang The histaminergic system: a target for innovative treatments of cognitive deficits Therapie 65 2010 415 422
254. M. Mousavi, and E. Hellstrom-Lindahl Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro Neurochem. Int. 54 2009 237 244
255. M. Mozayan, and T.J. Lee Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons Am. J. Physiol. Heart Circ. Physiol. 293 2007 H1737 H1744
256. T. Muayqil, and R. Camicioli Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Dement Geriatr. Cogn. Dis. Extra 2 2012 546 572
257. M.P. Murphy, and R.A. Smith Targeting antioxidants to mitochondria by conjugation to lipophilic cations Annu. Rev. Pharmacol. Toxicol. 47 2007 629 656
258. K. Nakaya, O. Nakagawasai, Y. Arai, H. Onogi, A. Sato, F. Niijima, K. Tan-No, and T. Tadano Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors Behav. Brain Res. 218 2011 165 173
259. N.N. Nalivaeva, C. Beckett, N.D. Belyaev, and A.J. Turner Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J. Neurochem. 120 Suppl. 1 2012 167 185
260. P.J. Nathan, R. Boardley, N. Scott, A. Berges, P. Maruff, T. Sivananthan, N. Upton, M.T. Lowy, P.J. Nestor, and R. Lai The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation Curr. Alzheimer Res. 10 2013 240 251
261. M. Necula, L. Breydo, S. Milton, R. Kayed, W.E. van der Veer, P. Tone, and C.G. Glabe Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization Biochemistry 46 2007 8850 8860 (Pubitemid 47208418)
262. C. Nelson, H.J. Wengreen, R.G. Munger, and C.D. Corcoran Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study J. Nutr. Health Aging 13 2009 899 905
263. R. Ni, A. Marutle, and A. Nordberg Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain J. Alzheimers Dis. 33 2013 841 851
264. N. Nicolakakis, T. Aboulkassim, B. Ongali, C. Lecrux, P. Fernandes, P. Rosa-Neto, X.K. Tong, and E. Hamel Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist J. Neurosci. 28 2008 9287 9296
265. A. Nikolaev, T. McLaughlin, D.D. O'Leary, and M. Tessier-Lavigne APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 457 2009 981 989
266. R.M. Nitsch, M. Deng, M. Tennis, D. Schoenfeld, and J.H. Growdon The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease Ann. Neurol. 48 2000 913 918
267. C. Niva, J. Parkinson, F. Olsson, E. van Schaick, J. Lundkvist, and S.A. Visser Has inhibition of Abeta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data Eur. J. Clin. Pharmacol. 69 2013 1247 1260
268. W. Noble, E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, K. Gaynor, L. Wang, J. LaFrancois, B. Feinstein, M. Burns, P. Krishnamurthy, Y. Wen, R. Bhat, J. Lewis, D. Dickson, and K. Duff Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. U. S. A. 102 2005 6990 6995 (Pubitemid 40675429)
269. A. Novelli, J.A. Reilly, P.G. Lysko, and R.C. Henneberry Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced Brain Res. 451 1988 205 212
270. I. Okun, S.E. Tkachenko, A. Khvat, O. Mitkin, V. Kazey, and A.V. Ivachtchenko From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon Curr. Alzheimer Res. 7 2010 97 112
271. J.M. Olcese, C. Cao, T. Mori, M.B. Mamcarz, A. Maxwell, M.J. Runfeldt, L. Wang, C. Zhang, X. Lin, G. Zhang, and G.W. Arendash Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease J. Pineal Res. 47 2009 82 96
272. T.G. Oliveira, R.B. Chan, H. Tian, M. Laredo, G. Shui, A. Staniszewski, H. Zhang, L. Wang, T.W. Kim, K.E. Duff, M.R. Wenk, O. Arancio, and G. Di Paolo Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits J. Neurosci. 30 2010 16419 16428
273. J.M. Orgogozo, J.F. Dartigues, S. Lafont, L. Letenneur, D. Commenges, R. Salamon, S. Renaud, and M.B. Breteler Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area Rev. Neurol. (Paris) 153 1997 185 192 (Pubitemid 27262834)
274. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank, and C. Hock Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46 54 (Pubitemid 36818745)
275. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, D.J. Brooks, W.E. Klunk, E. Ashford, K. Yoo, Z.X. Xu, H. Loetscher, and L. Santarelli Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch. Neurol. 69 2012 198 207
276. A.A. Othman, G. Haig, H. Florian, C. Locke, J. Zhang, and S. Dutta Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers Br. J. Clin. Pharmacol. 75 2013 1299 1311
277. K.P. Padala, P.R. Padala, D.P. McNeilly, J.A. Geske, D.H. Sullivan, and J.F. Potter The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study Am. J. Geriatr. Pharmacother. 10 2012 296 302
278. P.R. Padala, W.J. Burke, V.K. Shostrom, S.C. Bhatia, S.P. Wengel, J.F. Potter, and F. Petty Methylphenidate for apathy and functional status in dementia of the Alzheimer type Am. J. Geriatr. Psychiatry 18 2010 371 374
279. A. Parachikova, K.N. Green, C. Hendrix, and F.M. LaFerla Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease PLoS One 5 2010 e14015
280. S.H. Park, J.H. Kim, S.S. Bae, K.W. Hong, D.S. Lee, J.Y. Leem, B.T. Choi, and H.K. Shin Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation Biochem. Biophys. Res. Commun. 408 2011 602 608
281. W.D. Parker Jr., J. Parks, C.M. Filley, and B.K. Kleinschmidt-DeMasters Electron transport chain defects in Alzheimer's disease brain Neurology 44 1994 1090 1096 (Pubitemid 24188184)
282. L. Parnetti, S. Amici, A. Lanari, C. Romani, C. Antognelli, N. Andreasen, L. Minthon, P. Davidsson, H. Pottel, K. Blennow, and V. Gallai Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors Neurol. Sci. 23 Suppl. 2 2002 S95 S96
283. R.H. Parri, and T.K. Dineley Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences Curr. Alzheimer Res. 7 2010 27 39
284. C.G. Parsons, W. Danysz, A. Dekundy, and I. Pulte Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease Neurotox. Res. 2013 http://dx.doi.org/07/s12640-013-9398-z
285. A. Patat, V. Parks, S. Raje, A. Plotka, D. Chassard, and F. Le Coz Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects Br. J. Clin. Pharmacol. 67 2009 299 308
286. S.L. Payao, M.D. Smith, and P.H. Bertolucci Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease Gerontology 44 1998 267 271 (Pubitemid 28403387)
287. E.R. Peskind, S.G. Potkin, N. Pomara, B.R. Ott, S.M. Graham, J.T. Olin, and S. McDonald Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial Am. J. Geriatr. Psychiatry 14 2006 704 715 (Pubitemid 44196270)
288. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, E. Pfeiffer, M. Sano, C.H. van Dyck, and L.J. Thal Vitamin E and donepezil for the treatment of mild cognitive impairment N. Engl. J. Med. 352 2005 2379 2388 (Pubitemid 40958434)
289. M. Pfaffendorf, T.A. Bruning, H.D. Batnik, and P.A. van Zwieten The interaction between methylene blue and the cholinergic system Br. J. Pharmacol. 122 1997 95 98 (Pubitemid 27376024)
290. T. Pinto, K.L. Lanctot, and N. Herrmann Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type Ageing Res. Rev. 10 2011 404 412
291. G.L. Plosker, and S. Gauthier Cerebrolysin: a review of its use in dementia Drugs Aging 26 2009 893 915
292. A.P. Porsteinsson, G.T. Grossberg, J. Mintzer, and J.T. Olin Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial Curr. Alzheimer Res. 5 2008 83 89 (Pubitemid 351536358)
293. D.L. Price, D.W. Bonhaus, and K. McFarland Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease Behav. Pharmacol. 23 2012 426 433
294. J. Prickaerts, N.P. van Goethem, R. Chesworth, G. Shapiro, F.G. Boess, C. Methfessel, O.A. Reneerkens, D.G. Flood, D. Hilt, M. Gawryl, S. Bertrand, D. Bertrand, and G. Konig EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors Neuropharmacology 62 2012 1099 1110
295. D. Puzzo, A. Staniszewski, S.X. Deng, L. Privitera, E. Leznik, S. Liu, H. Zhang, Y. Feng, A. Palmeri, D.W. Landry, and O. Arancio Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model J. Neurosci. 29 2009 8075 8086
296. W. Qin, V. Haroutunian, P. Katsel, C.P. Cardozo, L. Ho, J.D. Buxbaum, and G.M. Pasinetti PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia Arch. Neurol. 66 2009 352 361
297. B. Qu, P.J. Boyer, S.A. Johnston, L.S. Hynan, and R.N. Rosenberg Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice J. Neurol. Sci. 244 2006 151 158
298. B. Qu, R.N. Rosenberg, L. Li, P.J. Boyer, and S.A. Johnston Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease Arch. Neurol. 61 2004 1859 1864 (Pubitemid 39612946)
299. J. Quinn, D. Kulhanek, J. Nowlin, R. Jones, D. Pratico, J. Rokach, and R. Stackman Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials Brain Res. 1037 2005 209 213 (Pubitemid 40362399)
300. M.S. Rafii, S. Walsh, J.T. Little, K. Behan, B. Reynolds, C. Ward, S. Jin, R. Thomas, and P.S. Aisen A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology 76 2011 1389 1394
301. J. Ramirez-Bermudez Alzheimer's disease: critical notes on the history of a medical concept Arch. Med. Res. 43 8 2012 595 599
302. G. Rammes, R. Rupprecht, U. Ferrari, W. Zieglgansberger, and C.G. Parsons The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner Neurosci. Lett. 306 2001 81 84 (Pubitemid 32524303)
303. G. Rammes, W. Danysz, and C.G. Parsons Pharmacodynamics of memantine: an update. Curr. Neuropharmacol 6 2008 55 78
304. G. Rammes, A. Hasenjager, K. Sroka-Saidi, J.M. Deussing, and C.G. Parsons Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices Neuropharmacology 60 2011 982 990
305. C.P. Ramsey, C.A. Glass, M.B. Montgomery, K.A. Lindl, G.P. Ritson, L.A. Chia, R.L. Hamilton, C.T. Chu, and K.L. Jordan-Sciutto Expression of Nrf2 in neurodegenerative diseases J. Neuropathol. Exp. Neurol. 66 2007 75 85 (Pubitemid 46066791)
306. M.A. Reger, G.S. Watson, P.S. Green, L.D. Baker, B. Cholerton, M.A. Fishel, S.R. Plymate, M.M. Cherrier, G.D. Schellenberg, W.H. Frey 2nd, and S. Craft Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults J. Alzheimers Dis. 13 2008 323 331 (Pubitemid 352039034)
307. P.R. Reid, T.M. Bridges, D.J. Sheffler, H.P. Cho, L.M. Lewis, E. Days, J.S. Daniels, C.K. Jones, C.M. Niswender, C.D. Weaver, P.J. Conn, C.W. Lindsley, and M.R. Wood Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe Bioorg. Med. Chem. Lett. 21 2011 2697 2701
308. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, B.A. Norman, and C.C. Baranak Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71 (Pubitemid 38082872)
309. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, R.W. Lent, S. Younkin, L. Younkin, R. Schiff, and M.E. Weksler 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol. Aging 30 2009 1728 1736
310. T.J. Revett, G.B. Baker, J. Jhamandas, and S. Kar Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology J. Psychiatry Neurosci. 38 2013 6 23
311. G.P. Reynolds, S.L. Mason, A. Meldrum, S. De Keczer, H. Parnes, R.M. Eglen, and E.H. Wong 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases Br. J. Pharmacol. 114 1995 993 998
312. A. Riccio, R.S. Alvania, B.E. Lonze, N. Ramanan, T. Kim, Y. Huang, T.M. Dawson, S.H. Snyder, and D.D. Ginty A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons Mol. Cell 21 2006 283 294 (Pubitemid 43099943)
313. M.W. Riepe, G. Adler, B. Ibach, B. Weinkauf, F. Tracik, and I. Gunay Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine Dement Geriatr. Cogn. Disord. 23 2007 301 306 (Pubitemid 46631935)
314. J.M. Ringman, G. Cole, E. Teng, V. Badmaev, J. Bardens, S. Frautschy, E. Rosario, J. Fein, V. Porter, Z. Vanek, C. Sugar, A. Yau, and J.L. Cummings P4-344: oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study Alzheimer's Demen. The J. Alzheimer's Assoc. 4 2008 T774
315. R.A. Rissman, A.L. De Blas, and D.M. Armstrong GABA(A) receptors in aging and Alzheimer's disease J. Neurochem. 103 2007 1285 1292 (Pubitemid 47631802)
316. C.W. Ritchie, A.I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R.E. Tanzi, and C.L. Masters Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch. Neurol. 60 2003 1685 1691 (Pubitemid 37521621)
317. J.J. Rodriguez, H.N. Noristani, and A. Verkhratsky The serotonergic system in ageing and Alzheimer's disease Prog. Neurobiol. 99 2012 15 41
318. S.L. Rogers, R.S. Doody, R.D. Pratt, and J.R. Ieni Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study Eur. Neuropsychopharmacol. 10 2000 195 203 (Pubitemid 30227620)
319. A.E. Roher, D.H. Cribbs, R.C. Kim, C.L. Maarouf, C.M. Whiteside, T.A. Kokjohn, I.D. Daugs, E. Head, C. Liebsack, G. Serrano, C. Belden, M.N. Sabbagh, and T.G. Beach Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 8 2013 e59735
320. L.E. Rojo, J. Alzate-Morales, I.N. Saavedra, P. Davies, and R.B. Maccioni Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease J. Alzheimers Dis. 19 2010 573 589
321. H. Rosenmann Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies Curr. Alzheimer Res. 10 2013 217 228
322. H. Rosenmann, N. Grigoriadis, D. Karussis, M. Boimel, O. Touloumi, H. Ovadia, and O. Abramsky Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein Arch. Neurol. 63 2006 1459 1467 (Pubitemid 44547559)
323. J. Ross, D. Brough, R.M. Gibson, S.A. Loddick, and N.J. Rothwell A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat Neuropharmacology 53 2007 638 642 (Pubitemid 47513170)
324. M.N. Sabbagh, A. Agro, J. Bell, P.S. Aisen, E. Schweizer, and D. Galasko PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis. Assoc. Disord. 25 2011 206 212
325. A. Sagare, R. Deane, R.D. Bell, B. Johnson, K. Hamm, R. Pendu, A. Marky, P.J. Lenting, Z. Wu, T. Zarcone, A. Goate, K. Mayo, D. Perlmutter, M. Coma, Z. Zhong, and B.V. Zlokovic Clearance of amyloid-beta by circulating lipoprotein receptors Nat. Med. 13 2007 1029 1031 (Pubitemid 47517512)
326. T. Saito, N. Iwata, S. Tsubuki, Y. Takaki, J. Takano, S.M. Huang, T. Suemoto, M. Higuchi, and T.C. Saido Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation Nat. Med. 11 2005 434 439 (Pubitemid 40562335)
327. S.G. Sala, U. Munoz, F. Bartolome, F. Bermejo, and A. Martin-Requero HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects J. Pharmacol. Exp. Ther. 324 2008 352 359 (Pubitemid 350294160)
328. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L.S. Honig, R. Doody, C.H. van Dyck, R. Mulnard, J. Barakos, K.M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, and M. Grundman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
329. R.O. Sanchez-Mejia, J.W. Newman, S. Toh, G.Q. Yu, Y. Zhou, B. Halabisky, M. Cisse, K. Scearce-Levie, I.H. Cheng, L. Gan, J.J. Palop, J.V. Bonventre, and L. Mucke Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease Nat. Neurosci. 11 2008 1311 1318
330. M. Sano, K.L. Bell, D. Galasko, J.E. Galvin, R.G. Thomas, C.H. van Dyck, and P.S. Aisen A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 77 2011 556 563
331. I. Santa-Maria, F. Hernandez, J. Del Rio, F.J. Moreno, and J. Avila Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau Mol. Neurodegener. 2 2007 17
332. 2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs PLoS One 3 2008 e2718
333. D. Saumier, A. Duong, D. Haine, D. Garceau, and J. Sampalis Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study J. Nutr. Health Aging 13 2009 808 812
334. C.L. Sayas, M.T. Moreno-Flores, J. Avila, and F. Wandosell The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation J. Biol. Chem. 274 1999 37046 37052
335. E.L. Schaeffer, V.J. De-Paula, E.R. da Silva, A.N.B. de, H.D. Skaf, O.V. Forlenza, and W.F. Gattaz Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein J. Neural Transm. 118 2011 1273 1279
336. E.L. Schaeffer, O.V. Forlenza, and W.F. Gattaz Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease Psychopharmacology (Berl) 202 2009 37 51
337. D. Schenk, G.S. Basi, and M.N. Pangalos Treatment strategies targeting amyloid beta-protein Cold Spring Harb. Perspect. Med. 2 2012 a006387
338. R. Schliebs, and T. Arendt The significance of the cholinergic system in the brain during aging and in Alzheimer's disease J. Neural Transm. 113 2006 1625 1644 (Pubitemid 44657659)
339. L.S. Schneider, K.S. Dagerman, J.P. Higgins, and R. McShane Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch. Neurol. 68 2011 991 998
340. L.E. Scott, M. Telpoukhovskaia, C. Rodriguez-Rodriguez, M. Merkel, M.L. Bowen, B.D.G. Page, D.E. Green, T. Storr, F. Thomas, D.D. Allen, P.R. Lockman, B.O. Patrick, M.J. Adam, and C. Orvig N-Aryl-substituted 3-([small beta]-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy Chem. Sci. 2 2011 642 648
341. M.L. Selenica, H.S. Jensen, A.K. Larsen, M.L. Pedersen, L. Helboe, M. Leist, and J. Lotharius Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation Br. J. Pharmacol. 152 2007 959 979 (Pubitemid 350100498)
342. K.T. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, A. Brossi, Y.W. Ge, D.K. Lahiri, and N.H. Greig Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development Proc. Natl. Acad. Sci. U. S. A. 98 2001 7605 7610 (Pubitemid 32567995)
343. E. Shemesh, A. Rudich, I. Harman-Boehm, and T. Cukierman-Yaffe Effect of intranasal insulin on cognitive function: a systematic review J. Clin. Endocrinol. Metab. 97 2012 366 376
344. F. Shen, J.A. Smith, R. Chang, D.L. Bourdet, P.R. Tsuruda, G.P. Obedencio, and D.T. Beattie 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment Neuropharmacology 61 2011 69 79
345. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, and R.G. Westendorp Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
346. 2+ dyshomeostasis that is blocked by EGb761 Neurochem. Int. 56 2010 893 905
347. M. Shibata, S. Yamada, S.R. Kumar, M. Calero, J. Bading, B. Frangione, D.M. Holtzman, C.A. Miller, D.K. Strickland, J. Ghiso, and B.V. Zlokovic Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier J. Clin. Invest. 106 2000 1489 1499 (Pubitemid 32038587)
348. S. Shimohama, Y. Sasaki, S. Fujimoto, S. Kamiya, T. Taniguchi, T. Takenawa, and J. Kimura Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease Neuroscience 82 1998 999 1007 (Pubitemid 27502045)
349. S.L. Siedlak, G. Casadesus, K.M. Webber, M.A. Pappolla, C.S. Atwood, M.A. Smith, and G. Perry Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease Free Radic. Res. 43 2009 156 164
350. E.R. Siemers, S. Friedrich, R.A. Dean, C.R. Gonzales, M.R. Farlow, S.M. Paul, and R.B. Demattos Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease Clin. Neuropharmacol. 33 2010 67 73
351. V. Skov, D. Glintborg, S. Knudsen, Q. Tan, T. Jensen, T.A. Kruse, H. Beck-Nielsen, and K. Hojlund Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome PLoS One 3 2008 e2466
352. T.A. Slotkin, F.J. Seidler, B.J. Crain, J.M. Bell, G. Bissette, and C.B. Nemeroff Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy Proc. Natl. Acad. Sci. U. S. A. 87 1990 2452 2455
353. A. Smith, B. Giunta, P.C. Bickford, M. Fountain, J. Tan, and R.D. Shytle Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease Int. J. Pharm. 389 2010 207 212
354. B.J. Snow, F.L. Rolfe, M.M. Lockhart, C.M. Frampton, J.D. O'Sullivan, V. Fung, R.A. Smith, M.P. Murphy, and K.M. Taylor A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease Mov Disord. 25 2010 1670 1674
355. R. Sperling, S. Salloway, D.J. Brooks, D. Tampieri, J. Barakos, N.C. Fox, M. Raskind, M. Sabbagh, L.S. Honig, A.P. Porsteinsson, I. Lieberburg, H.M. Arrighi, K.A. Morris, Y. Lu, E. Liu, K.M. Gregg, H.R. Brashear, G.G. Kinney, R. Black, and M. Grundman Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis Lancet Neurol. 11 2012 241 249
356. J.G. Stone, G. Casadesus, K. Gustaw-Rothenberg, S.L. Siedlak, X. Wang, X. Zhu, G. Perry, R.J. Castellani, and M.A. Smith Frontiers in Alzheimer's disease therapeutics Ther. Adv. Chronic Dis. 2 1 2011 9 23
357. T.P. Storozhevykh, Y.E. Senilova, T. Brustovetsky, V.G. Pinelis, and N. Brustovetsky Neuroprotective effect of KB-R7943 against glutamate excitotoxicity is related to mild mitochondrial depolarization Neurochem. Res. 35 2010 323 335
358. C.A. Szekely, J.C. Breitner, A.L. Fitzpatrick, T.D. Rea, B.M. Psaty, L.H. Kuller, and P.P. Zandi NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type Neurology 70 2008 17 24
359. P.N. Tariot, P. Aisen, J. Cummings, L. Jakimovich, L. Schneider, R. Thomas, L. Becerra, and R. Loy The ADCS valproate neuroprotection trial: primary efficacy and safety results Alzheimer's Demen. The J. Alzheimer's Assoc. 5 2009 P84 P85
360. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald, and I. Gergel Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA 291 2004 317 324 (Pubitemid 38101604)
361. P.N. Tariot, L.S. Schneider, J. Cummings, R.G. Thomas, R. Raman, L.J. Jakimovich, R. Loy, B. Bartocci, A. Fleisher, M.S. Ismail, A. Porsteinsson, M. Weiner, C.R. Jack Jr., L. Thal, and P.S. Aisen Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch. Gen. Psychiatry 68 2011 853 861
362. H.O. Tayeb, E.D. Murray, B.H. Price, and F.I. Tarazi Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin. Biol. Ther. 13 7 2013 1075 1084
363. L.J. Thal, M. Grundman, J. Berg, K. Ernstrom, R. Margolin, E. Pfeiffer, M.F. Weiner, E. Zamrini, and R.G. Thomas Idebenone treatment fails to slow cognitive decline in Alzheimer's disease Neurology 61 2003 1498 1502 (Pubitemid 37505568)
364. J. Toyohara, and K. Hashimoto alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease Open Med. Chem. J. 4 2010 37 56
365. T. Truelsen, D. Thudium, and M. Gronbaek Amount and type of alcohol and risk of dementia: the Copenhagen city heart study Neurology 59 2002 1313 1319 (Pubitemid 35285979)
366. M.H. Tuszynski, L. Thal, M. Pay, D.P. Salmon, H.S. U, R. Bakay, P. Patel, A. Blesch, H.L. Vahlsing, G. Ho, G. Tong, S.G. Potkin, J. Fallon, L. Hansen, E.J. Mufson, J.H. Kordower, C. Gall, and J. Conner A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat. Med. 11 2005 551 555 (Pubitemid 40691288)
367. B. Vellas, R. Black, L.J. Thal, N.C. Fox, M. Daniels, G. McLennan, C. Tompkins, C. Leibman, M. Pomfret, and M. Grundman Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders Curr. Alzheimer Res. 6 2009 144 151
368. B. Vellas, N. Coley, P.J. Ousset, G. Berrut, J.F. Dartigues, B. Dubois, H. Grandjean, F. Pasquier, F. Piette, P. Robert, J. Touchon, P. Garnier, H. Mathiex-Fortunet, and S. Andrieu Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial Lancet Neurol. 11 2012 851 859
369. B. Vellas, O. Sol, P.J. Snyder, P.J. Ousset, R. Haddad, M. Maurin, J.C. Lemarie, L. Desire, and M.P. Pando EHT0202 in Alzheimer's disease: a 3-Month, randomized, placebo-controlled, double-blind study Curr. Alzheimer Res. 8 2011 203 212
370. V. Vijayapadma, P. Ramyaa, D. Pavithra, and R. Krishnaswamy Protective effect of lutein against benzo(a)pyrene-induced oxidative stress in human erythrocytes Toxicol. Ind. Health 2012 10.1177/0748233712457439
371. M.T. Vilaro, R. Cortes, and G. Mengod Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions J. Comp. Neurol. 484 2005 418 439 (Pubitemid 40477971)
372. M.P. Vitek, C.M. Brown, and C.A. Colton APOE genotype-specific differences in the innate immune response Neurobiol. Aging 30 2009 1350 1360
373. R. Vozzo, G.A. Wittert, M. Horowitz, J.E. Morley, and I.M. Chapman Effect of nitric oxide synthase inhibitors on short-term appetite and food intake in humans Am. J. Physiol. 276 1999 R1562 R1568
374. L.U. Wahlberg, G. Lind, P.M. Almqvist, P. Kusk, J. Tornoe, B. Juliusson, M. Soderman, E. Sellden, A. Seiger, M. Eriksdotter-Jonhagen, and B. Linderoth Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery J. Neurosurg. 117 2012 340 347
375. T.L. Wallace, and D. Bertrand Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex Biochem. Pharmacol. 85 12 2013 1713 1720
376. T. Walle Bioavailability of resveratrol Ann. N. Y. Acad. Sci. 1215 2011 9 15
377. J.-z. Wang, and Z.-f. Wang Role of melatonin in Alzheimer-like neurodegeneration Acta Pharmacol. Sin 27 2006 41 49
378. P. Wang, J.G. Myers, P. Wu, B. Cheewatrakoolpong, R.W. Egan, and M.M. Billah Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D Biochem. Biophys. Res. Commun. 234 1997 320 324 (Pubitemid 27243900)
379. T. Wang, C.Y. Wang, Z.Y. Shan, W.P. Teng, and Z.Y. Wang Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AbetaPP/PS1 transgenic mouse brain J. Alzheimers Dis. 29 2012 549 559
380. X. Wang, B. Su, H.G. Lee, X. Li, G. Perry, M.A. Smith, and X. Zhu Impaired balance of mitochondrial fission and fusion in Alzheimer's disease J. Neurosci. 29 2009 9090 9103
381. P.B. Watkins, H.J. Zimmerman, M.J. Knapp, S.I. Gracon, and K.W. Lewis Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease JAMA 271 1994 992 998 (Pubitemid 24099919)
382. S.J. Webster, S. Mruthinti, W.D. Hill, J.J. Buccafusco, and A.V. Terry Jr. An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease Neuromolecular Med. 14 2012 119 130
383. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, A. Fauq, T.E. Golde, and E.H. Koo Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity J. Biol. Chem. 278 2003 31831 31837 (Pubitemid 37048365)
384. M. Weinstock, C. Bejar, R.H. Wang, T. Poltyrev, A. Gross, J.P. Finberg, and M.B. Youdim TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease J. Neural Transm. Suppl. 2000 157 169 (Pubitemid 32037191)
385. M.E. Weksler, N. Relkin, R. Turkenich, S. LaRusse, L. Zhou, and P. Szabo Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals Exp. Gerontol. 37 2002 943 948 (Pubitemid 34665486)
386. Y. Wen, W. Li, E.C. Poteet, L. Xie, C. Tan, L.J. Yan, X. Ju, R. Liu, H. Qian, M.A. Marvin, M.S. Goldberg, H. She, Z. Mao, J.W. Simpkins, and S.H. Yang Alternative mitochondrial electron transfer as a novel strategy for neuroprotection J. Biol. Chem. 286 18 2011 16504 16515
387. G.K. Wilcock, C.G. Ballard, J.A. Cooper, and H. Loft Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies J. Clin. Psychiatry 69 2008 341 348 (Pubitemid 351549385)
388. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, T. Dumortier, R.P. Maguire, K. Blennow, J. Lundmark, M. Staufenbiel, J.M. Orgogozo, and A. Graf Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol. 11 2012 597 604
389. B. Winblad, G. Grossberg, L. Frolich, M. Farlow, S. Zechner, J. Nagel, and R. Lane IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease Neurology 69 2007 S14 S22
390. C.M. Wischik, P. Bentham, D.J. Wischik, and K.M. Seng O3-04-07: tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks Alzheimer's Demen. The J. Alzheimer's Assoc. 4 2008 T167
391. T.M. Wright Tramiprosate Drugs Today (Barc) 42 2006 291 298 (Pubitemid 43980714)
392. H. Xiao, Y. Su, X. Cao, S. Sun, and Z. Liang A meta-analysis of mood stabilizers for Alzheimer's disease J. Huazhong Univ. Sci. Technol. Med. Sci. 30 2010 652 658
393. Y. Xu, J. Yan, P. Zhou, J. Li, H. Gao, Y. Xia, and Q. Wang Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease Prog. Neurobiol. 97 2012 1 13
394. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P. Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, and G.M. Cole Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 2005 5892 5901 (Pubitemid 40280072)
395. Y. Yang, D. Ma, Y. Wang, T. Jiang, S. Hu, M. Zhang, X. Yu, and C.X. Gong Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes J. Alzheimers Dis. 33 2013 329 338
396. K. Yasojima, E.G. McGeer, and P.L. McGeer Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain Brain Res. 919 2001 115 121 (Pubitemid 33016594)
397. S. Yoshimura, R. Morishita, K. Hayashi, K. Yamamoto, H. Nakagami, Y. Kaneda, N. Sakai, and T. Ogihara Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy Gene Ther. 8 2001 1635 1642 (Pubitemid 33085585)
398. M.B. Youdim, and J.J. Buccafusco Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders Trends Pharmacol. Sci. 26 2005 27 35 (Pubitemid 40052707)
399. M.B. Youdim, and M. Weinstock Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate] Cell Mol. Neurobiol. 21 2001 555 573 (Pubitemid 34538855)
400. Q.S. Yu, M. Reale, M.A. Kamal, H.W. Holloway, W. Luo, K. Sambamurti, B. Ray, D.K. Lahiri, J.T. Rogers, and N.H. Greig Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, alpha-synuclein synthesis, interleukin-1beta release, and cholinergic action Antiinflamm. Antiallergy Agents Med. Chem. 12 2 2013 117 128
401. Y. Yu, L. Zhang, X. Li, X. Run, Z. Liang, Y. Li, Y. Liu, M.H. Lee, I. Grundke-Iqbal, K. Iqbal, D.J. Vocadlo, F. Liu, and C.X. Gong Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation PLoS One 7 2012 e35277
402. Y. Yue, L. Hu, Q.J. Tian, J.M. Jiang, Y.L. Dong, Z.Y. Jin, Y.H. Cheng, X. Hong, Q.S. Ge, and P.P. Zuo Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes Acta Pharmacol. Sin 28 2007 1129 1135 (Pubitemid 47197784)
403. P.P. Zandi, M.C. Carlson, B.L. Plassman, K.A. Welsh-Bohmer, L.S. Mayer, D.C. Steffens, and J.C. Breitner Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study JAMA 288 2002 2123 2129 (Pubitemid 35265379)
404. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, J. Bruce, E.B. Lee, S.X. Xie, S. Joyce, C. Li, P.M. Toleikis, V.M. Lee, and J.Q. Trojanowski Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc. Natl. Acad. Sci. U. S. A. 102 2005 227 231 (Pubitemid 40094457)
405. H.Y. Zhang, H. Yan, and X.C. Tang Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase Cell Mol. Neurobiol. 28 2008 173 183 (Pubitemid 351253069)
406. H. Zhao, M.L. Michaelis, and B.S. Blagg Hsp90 modulation for the treatment of Alzheimer's disease Adv. Pharmacol. 64 2012 1 25
407. X. Zhu, H.G. Lee, G. Perry, and M.A. Smith Alzheimer disease, the two-hit hypothesis: an update Biochim. Biophys. Acta 1772 2007 494 502 (Pubitemid 46400383)
408. B.V. Zlokovic Clearing amyloid through the blood-brain barrier J. Neurochem. 89 2004 807 811 (Pubitemid 38684728)